Skip to content

Arrowhead Research ARWR Other Non-Current Assets

Other Non-Current Assets at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$135.56M+2.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$18.62M+12.1%
Royalty Pharma logo
Royalty PharmaRPRX
$16.54B+10.0%
Revvity logo
RevvityRVTY
$322.1M+7.5%
ALN
Alnylam PharmaceuticalsALNY
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$11.52B+402%
Enterprise value$11.44B+418%
P/S18.5×+14.3×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arrowhead Research's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arrowhead Research's other non-current assets?
Arrowhead Research (ARWR) reported other non-current assets of $4.89M in Q1 2026.
How has Arrowhead Research's other non-current assets changed year-over-year?
Arrowhead Research's other non-current assets increased by 272.5% year-over-year, from $1.31M to $4.89M.
What is the long-term trend for Arrowhead Research's other non-current assets?
Over 5 years (2020 to 2025), Arrowhead Research's other non-current assets has grown at a 39.4% compound annual growth rate (CAGR), from $264K to $1.39M.
What does other non-current assets mean?
Miscellaneous long-term assets that do not fit into other specific categories.
How do you interpret other non-current assets?
Large changes may warrant investigation into non-core investments or changes in long-term contractual obligations.
How does other non-current assets compare across companies?
Typically a small, non-material portion of the balance sheet for most biotech companies.